Clinical trials: GLP - 1
Metabolic Disturbance, Schizophrenia
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Background and objective: Clozapine and olanzapine are some of the most effective antipsychotic drugs, but unfortunately, both drugs induce weight gain and conveys a high degree of metabolic disturbances.
- Conditions
- Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine
- Trial name
- NCT04892199
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- 3 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Obesity & Overweight
Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss
The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or…
- Trial name
- NCT07611552
- Testing
- inulin (prebiotics)
- Where
- 5 sites in China
- Volunteers
- 600 people
- Sponsor
- Huazhong University of Science and Technology
Smoking Cessation
Exenatide Once Weekly for Smoking Cessation
The purpose of this study is to identify a potential new treatment for smoking cessation.
- Trial name
- NCT02975297
- Testing
- Exenatide, NRT, Counseling
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type 2 Diabetes Mellitus
Tofogliflozin GLP-1 Analogue Combination Trial
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
- Trial name
- NCT02537834
- Testing
- Tofogliflozin, GLP-1 analogue
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Kowa Company, Ltd.
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Type 2 Diabetes Mellitus
Glucolipotoxicity and Type 2 Diabetes
Elevations of blood glucose and lipid are thought to be deleterious to the insulin secretory function of the pancreas. This is known as glucolipotoxicity. However, few studies have examined this in detail.
- Trial name
- NCT01375270
- Testing
- Glucotoxicity, Lipotoxicity
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Alcohol Abuse, Alcohol Addiction
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of the GLP-1 receptor agonist semaglutide s.c.
- Conditions
- Alcohol Abuse, Alcohol Addiction, Alcohol Dependence, Alcohol Use Disorder
- Trial name
- SEMALCO (NCT05895643)
- Testing
- Semaglutide Injectable Product
- Where
- Denmark
- Volunteers
- 108 people
- Sponsor
- Psychiatric Centre Rigshospitalet
Appetite and General Nutritional Disorders
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
The aim is to further establish a physiological role for GLP-1 as an endogenous satiety signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on appetite and food intake in healthy male subjects.
- Trial name
- NCT01900340
- Testing
- Saline, Exendin 9-39, Exendin(9-39) plus ID nutrient
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
GLP - 1, Bowel Preparation for Colonoscopy
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies.
- Trial name
- NCT07127354
- Testing
- Continue GLP/GIP
- Where
- 3 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Glucose Homeostasis
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly…
- Trial name
- NCT00947011
- Testing
- Januvia
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Periodontal Disease, Obesity & Overweight
Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy
This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.
- Trial name
- GLP1-PERIO (NCT07770906)
- Testing
- non-surgical periodontal therapy
- Volunteers
- 40 people
- Sponsor
- Cukurova University
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Arthritis, Obesity & Overweight
GLP-1s in Hip and Knee Arthroplasty
The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity.
- Conditions
- Arthritis, Obesity & Overweight, GLP - 1
- Trial name
- NCT07755085
- Testing
- GLP-1 Receptor Agonists + Behavioral modification
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Nova Scotia Health Authority
Weight Loss, Nutritional Deficiencies
Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial
Rationale: Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as effective treatments for obesity and associated medical conditions.
- Conditions
- Weight Loss, Nutritional Deficiencies, GLP - 1, Obese Patients
- Trial name
- VITAGLP (NCT07234916)
- Testing
- Multivitamin Supplementation
- Where
- 2 sites in Netherlands
- Volunteers
- 246 people
- Sponsor
- Erasmus Medical Center